NCT01460498 - Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2012

Primary Completion Date

August 7, 2019

Study Completion Date

August 7, 2019

Conditions

Leukemia

Interventions

DRUG

Azacitidine (AZA)

Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.

DRUG

Tyrosine kinase inhibitor (TKI)

Continuation of dose already receiving during previous 6 months.

DRUG

Azacitidine

75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston